Hemorrhagic complications during warfarin treatment;Krvácivé komplikace při léčbě warfarinem

Vnitrni Lekarstvi

Volumn 52, Issue SUPPL. 1, 2006, Pages 79-91

  Gumulec, Jaromír ^a   Kessler, P ^b   Penka, M ^c   Klodova D ^a   Kralova S ^a   Brejcha, M ^a   Wrobel M ^a   Sumna E ^a   Blatny J ^c   Klaricova K ^a   Riedlova P ^a   Lasota, Z ^a  

^a Onkologické Centrum J G Mendla   (Czech Republic)

^b Odd lení Hematologie a Transfuziologie   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Bleeding; Plasma; Prothrombin complex concentrate; Recombinant activated F VII; Vitamin K; Warfarin

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; HUMAN; INTERNATIONAL NORMALIZED RATIO; PLASMA TRANSFUSION;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION FACTORS; DRUG MONITORING; FACTOR VIIA; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PLASMA; VITAMIN K 1; WARFARIN;

EID: 33645473858     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1986; 89: 16-25.
2. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1989; 95: 26-36.
3. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation. Br J Haematol 2001; 114: 271-280.
4. Černý V, Cvachovec K, Kasal M et al. Zásady podpory koagulace u život ohrožujícího a neztišitelného krvácení. Dostupné na www.thrombosis.cz.
5. Hull R, Hirsh J, Jay R et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1671-1681.
6. Turpie AGG, Gunstensen J, Hirsh J et al. Randomized comparison of two intensities of oral anticoagulant therapy after heart valve replacement. Lancet 1988; 1: 1242-1245.
7. Saour JN, Sieck JO, Mamo LAR et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 428-432.
8. Altman R, Rouvier J, Gurfinkel E et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 427-431.
9. Algra A, Franke CL, Koehler PJJ et al. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-865.
10. Cannegieter SC, Rosendaal FR, Wintzen AR et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Eng J Med 1995; 333: 11-17.
11. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
12. Arial fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
13. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
14. Bern MM, Lokich JJ, Wallach SR et al. Very low doses of warfarin can prevent thrombosis in central vein catheters: a randomized prospective trial. Ann Intern Med 1990; 112: 423-428.
15. Levine M, Hirsh J, Gent M et al. Double-blind randomized trial of very low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889.
16. Lee AYY, Levine MN. Venous Thromboembolism and Cancer: Risk and Outcomes. Circulation 2003; 107: I-17-I-21.
17. Kearon C, Ginsberg JS, Kovacs MJ et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
18. Ridker PM, Goldhaber SZ, Danielson E et al. Long-term low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-1434.
19. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Arial Fibrillation III randomized clinical trial. Lancet 1996; 348: 633-638.
20. Fihn SD, McDonnel M, Martin D et al. Risk factors for complications of chronic anticoagulation: a multi-centre study. Ann Intern Med 1993; 118: 511-520.
21. Casais P, Luceros AS, Meschengieser S et al. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000; 63: 192-196.
22. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient's outcomes, health care costs. Arch Intern Med 1998; 158: 1641-1647.
23. Cortelazzo S, Finazzi P, Viero P et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993; 69: 316-320.
24. Garabedian-Rufalo SM, Gray DR, Sax MJ et al. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm 1985; 42: 304-308.
25. Wilt VM, Gums JG, Ahmed OI et al. Pharmacy operated anticoagulation service: improved outcomes in patients on warfarin. Pharmacotherapy 2003; 15: 732-779.
26. Anderson DR, Wilson JE, Wells PS et al. Anticoagulant clinic vs family physicians based warfarin monitoring: a randomized controlled trial (abstract). Blood 2000; 96: 846a.
27. Matcher D, Samsa G, Cohen S et al. Improving the quality of anticoagulation of patients with aerial fibrillation in managed care organizations: results of managing anticoagulation services trial. Am J Med 2002; 113: 42-51.
28. Beyth RJ, Quinn LM, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized clinical trial. Ann Intern Med 2000; 133: 687-695.
29. Elston-Lafata J, Martin SA, Kaatz S et al. The cost effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000; 15: 31-37.
30. White RH, McCurdy SA, von Marensdorff H et al. Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study. Ann Intern Med 1989; 111: 730-737.
31. Hasenkam JM, Kimose II, Knudson L et al. Self-management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg 1997; 11: 935-942.
32. Sawicki PT. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 1999; 281: 145-150.
33. Korke H, Korfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 2001; 72: 44-48.
34. Ansell J, Patel N, Ostrovsky D et al. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995; 155: 2185-2189.
35. Watzke HH, Forberg E, Svolba G et al. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000; 83: 661-665.
36. Cromheecke ME, Levi M, Coly LP et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison. Lancet 2000; 356: 97-102.
37. Pengo V, Legnani C, Noventa F et al. On behalf of the ISCOAT Study Group. Oral anticoagulant therapy in patients with nonrheumatic aerial fibrillation and risk of bleeding: a multicenter inception cohort study. Thromb Haemost 2001; 85: 418-422.
38. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-428.
39. Gitter MJ, Jaeger TM, Petterson TM et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-733.
40. Levine MN, Raskob G, Beyth RJ et al. Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 287-310.
41. Dickman LJ, Rettie AE, Kneller MB et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001; 60: 382-387.
42. Kidd RS, Cury TB, Gallagher S et al. Identification of a null allele of CYP2C9 in an African American exhibiting toxicity of fenytoin. Pharmacogenetics 2001; 11: 803-808.
43. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and metaanalysis. Genet Med 2005; 7: 97-104.
44. Peyvandi F, Spreafico M, Siboni M et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004; 75: 198-203.
45. Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-1698.
46. D'Andrea G, D'Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-649.
47. Yuan UY, Chen JJ, Lee MT et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751.
48. Oldenburg J, Quenzel EM, Harbrecht U et al. Missense mutations at ALA-10 in the factor IX propeptidu: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-244.
49. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
50. Landefeld S, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
51. Petitti D, Strom B, Melmon K. Duration of warfarin anticoagulation therapy and the probalities of recurrent thromboembolism and hemorrhage. Am J Med 1986; 81: 255-259.
52. McInnes GT, Helenglass G. The performance of clinics for outpatient control of anticoagulation. J R Coll Physicians Lond 1987; 21: 42-45.
53. Fuller JA, Melb MB. Experiences with long-term anticoagulant treatment. Lancet 1959; 2: 489-491.
54. Mosley DH, Schatz IJ, Breneman GM et al. Long-term anticoagulant therapy. JAMA 1963; 186: 914-916.
55. Torn M, Algra A et al. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology 2001; 57: 1933-1939.
56. Lundstrom R, Ryden L. Hemorrhagic and thromboembolic complications in patients with aerial fibrillation on anticoagulant prophylaxis. J Intern Med 1989; 225: 137-142.
57. Forfar JC. A 7-year analysis of hemorrhage in patients in long-term anticoagulant treatment. Br Heart J 1979; 42: 128-132.
58. Ansell J, Hirsh J, Poller L et al. The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204-233.
59. Hanley JP Warfarin reversal. J Clin Pathol 2004; 57: 1132-1139.
60. Gunneman T, Ruybalid RL, Jacobson AK et al. Frequent prothrombin time testing reduces inappropriate warfarin dose changes (abstract). Thromb Haemost 1999; 82(Suppl): 676.
61. Lousberg TR, Witt DM, Beall DG et al. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 1998; 158: 528-534.
62. Hylek EM, Regan S, Go AS et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135: 393-400.
63. Baker RI, Coughlin PB, Gallus AS et al. Warfarin reversal: consensus guidelines on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497.
64. Shetty HG, Backhouse G, Bentley OP et al. Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1. Thromb Haemost 1992; 67: 13-15.
65. Makris M, Graves M, Phillips WS et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-480.
66. Martin JC. Anaphylactoid reactions and vitamin K (letter). Med J Aust 1991; 155: 851.
67. Fiore LD, Scola MA, Cantillon CE et al. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001; 11: 175-183.
68. Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytomenadione for reversing excessive anticoagulation. Arch Intern Med 1998; 158: 2136-2140.
69. Raj G, Kumar R, McKinney P. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytomenadione. Arch Intern Med 1999; 159: 2721-2724.
70. Crowther MA, Douketis JD, Schnurr T et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. Ann Intern Med 2002; 137: 251-254.
71. Roche Products Konakion. Australian product information. Sydney: Roche Products Pty Ltd, 12 February 1998 (tablets and MM ampoules); 18 October 2000 (MM Paediatric).
72. Watson HG, Baglin T, Laidlaw SL et al. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115: 145-149.
73. Pengo V, Banzato A, Garelli E et al. Reversal of excessive effect of regular anticoagulation: low oral dose of phytomenadione (vitamine K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis 1993; 4: 739-741.
74. Cosgriff SW. The effectiveness of an oral vitamin K1 in controlling excessive hypoprothrombinaemia during anticoagulant therapy. Ann Intern Med 1956; 45: 12-22.
75. Shirger A, Spittel JAQ, Ragen PA et al. Small doses of vitamin K1 for correction of reduced prothrombin activity. Proc Mayo Clin 1959; 34: 453-458.
76. Weibert RE, Le DT, Kayser SR et al. Correction of excessive anticoagulation with low dose oral vitamin K1. Ann Intern Med 1997; 125: 959-962.
77. Nitu IC, Perry DJ, Lee CA. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol 1998; 20: 363-367.
78. Fredrikson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-977.
79. Boulis NM, Bobek MP, Schmaier A et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113-1119.
80. Cartmil M, Dolan G, Byrne JL et al. Prothrombin complex concentrates for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14: 458-461.
81. Preston FE, Laidlaw ST, Sampson B et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116: 619-624.
82. Evans G, Luddington R, Baglin T Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001; 115: 998-1001.
83. Yasaka M, Oomura M, Ikeno K et al. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Haematol 2003; 82: 121-123.
84. Optimal Use Of Blood: Summaries Of Component Characteristics. Council of Europe Publishing. Guide to the preparation, use and quality assurance of blood components 11th edition. Strasbourg, Council of Europe Publishing, 2005.
85. Erhardtsen E, Nony P, Dechavanne et al. The effect of recombinant factor VIIa (Novoseven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2,0. Blood Coagul Fibrinolysis 1998; 9: 741-748.
86. Deveras RAE, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137: 884-888.
87. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural haematoma. Med Sci Manit 2002; 8: 98-100.
88. Sorensen B, Johansen P, Nielsen GL et al. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14: 469-477.
89. Lin J, Hanigan WC, Tarantino M et al. The use of recombinant activated factor VII to reverse warfarin induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003; 98: 737-740.
90. Brody DL, Aiyagari V, Shackleford AM et al. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocritical Care 2005; 2: 263-267.
91. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation. Br J Haematol 2001; 114: 271-280.
92. Kessler P. Léčba orálními antikoagulancii. Praha: Orion - yhtymä Oyj, Orion Pharma 2002.
93. Matýšková M, Penka M. Interakce antikoagulač ních léků s potravinami a potravinovými doplňky. Přehledný článek. Interní medicína pro praxi 2000; 5: 29-33.
94. Penka M, Matýšková M, Buliková A et al. Příprava nemocného s dlouhodobou antikoagulač ní léčbou v ambulantní praxi k chirurgickému výkonu. Přehledný článek. Interní medicína pro praxi 2000; 5: 20-23.
95. Monagle P. Reply to rebuttal: A problem of calibration in the paper "Pont of care monitoring of oral anticoagulant therapy in children". Thromb Haemost 2005; 93: 623.
96. David GN (ed). Nathan and Oski's Hematology of Infanty and Childhood. 6th ed. Elsevier 2003.
97. Makris M, Watson HG. Reversal of coumarin-induced over-anticoagulation: reply to Escobar. Br J Haematol 2002; 118: 926.